Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis.

Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. Abstract Text:

Amit Roy,Diane R Mould,Xiao-Feng Wang,Lee Tay,Ralph Raymond,Marc Pfister,Amit Roy,Diane R Mould,Xiao-Feng Wang,Lee Tay,Ralph Raymond,Marc Pfister,

Abatacept is a recombinant soluble fusion protein that inhibits the CD80/CD86:CD28 costimulatory signal required for T cell activation and has demonstrated efficacy in the treatment of rheumatoid arthritis. The objectives of this analysis were to provide support for a body weight-tiered dosing regimen approximating 10 mg/kg by (1) quantifying the effect of body weight on exposure and (2) characterizing the relationship between exposure and serum interleukin (IL)-6 concentration. The abatacept exposure and exposure-response models were developed with 2148 abatacept serum concentrations (from 388 subjects) and 1894 IL-6 serum concentrations (from 799 subjects), respectively, followed by simulation with these models to address the above objectives. Abatacept exposure was characterized by a linear 2-compartmental model, in which clearance was linearly related to body weight. The IL-6 response was characterized by an indirect-response model, in which the IL-6 production rate increased with baseline C-reactive protein levels. Model-based simulations demonstrated that body weight-tiered dosing was desirable to ensure consistent steady-state abatacept trough concentrations across a range of body weights; doses approximating 10 mg/kg (500, 750, 1000 mg for subjects weighing <60, 60-100, and >100 kg, respectively) provided consistent exposure across the body weight groups. In addition, doses >10 mg/kg did not result in further increases in IL-6 suppression. These modeling and simulation results indicate that the body weight-tiered abatacept therapeutic doses approximating 10 mg/kg will ensure consistent abatacept exposure and optimal IL-6 suppression.

Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. Publishing Authors By Initials

A Roy,DR Mould,XF Wang,L Tay,R Raymond,M Pfister,A Roy,DR Mould,XF Wang,L Tay,R Raymond,M Pfister,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of clinical pharmacology

VOLUME: 47

Page Numbers: 1408-20

Journal Abbreviation:

ISSN: 0091-2700

DAY: 26

MONTH: Nov

YEAR: 2007

Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 366372

Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis.

AFFILIATION: Clinical Discovery, Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543-4000, USA. amit.roy@bms.com

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis Related Publications

• A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors.
• Aortic thromboxane receptor deficiency alters vascular reactivity in cholesterol-fed rabbits.
• Auricular fibrillation; its incidence in syphilitic heart disease.
• BUSINESS IN DENTISTRY.
• Breaking bounds: Alice Profe, radical and emancipationist.
• Concordance between short-term experiments and long-term censuses in tide pool fishes.
• Detection and molecular characterization of Babesia caballi and Theileria equi isolates from endemic areas of Brazil.
• Effects of productivity, consumers, competitors, and El Niño events on food chain patterns in a rocky intertidal community.
• Epidemiology of Dermanyssus gallinae and Acaricidal Efficacy of Phoxim 50% in Alternative Housing Systems during the Laying Period of Hens.
• Ex utero intrapartum treatment (EXIT), a resuscitation option for intra-thoracic foetal pathologies.
• Human papilloma virus (HPV)-associated gynecological alteration in mothers of children with recurrent respiratory papillomatosis during long-term observation.
• Interaction of the DYNLT (TCTEX1/RP3) Light Chains and the Intermediate Chains Reveals Novel Intersubunit Regulation during Assembly of the Dynein Complex.
• Interferon regulatory factor 5.2 acts as a transcription repressor of Epidermodysplasia verruciformis-associated human papillomaviruses.
• Intermediate chain subunit as a probe for cytoplasmic dynein function: biochemical analyses and live cell imaging in PC12 cells.
• Methods to study the interactions of the dynein light chains and intermediate chains.
• Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis.
• Multiparasitism, Production and Economics in Domestic Animals in sub-Saharan West Africa.
• Peripheral blood mononuclear cells (PBMCs): a possible model for studying cardiovascular biology systems.
• Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer.
• Reply.
• Substitured sulfaquinoxalines; extension of the glyoxalate synthesis of 2-aminoquinoxaline.
• The participation of Switzerland in the international aid for refugees and homeless persons.
• Viral strategies for intracellular trafficking: motors and microtubules.
• [Ascites paracentesis]
• [Book review.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Sympathetic ganglion degeneration in the spinal dog.]